Experts has a new look! Let us know what you think of the updates.

Provide feedback
Home
Scholarly Works
BNT162b2 mRNA COVID-19 against symptomatic Omicron...
Journal article

BNT162b2 mRNA COVID-19 against symptomatic Omicron infection following a mass vaccination campaign in southern Brazil: A prospective test-negative design study

Abstract

BACKGROUND: Evidence regarding effectiveness of BNT162b2 mRNA COVID-19 vaccine against Omicron in Latin America is limited. We estimated BNT162b2 effectiveness against symptomatic COVID-19 in Brazil when Omicron was predominant. METHODS: This prospective test-negative, case-control study was conducted in Toledo, Brazil, following a mass COVID-19 vaccination with BNT162b2. Patients were included if they were aged ≥12 years, sought care for acute …

Authors

Rosa RG; Falavigna M; Manfio JL; de Araujo CLP; Cohen M; do Valle Barbosa GRG; de Souza AP; Silva FKR; Sganzerla D; da Silva MMD

Journal

Vaccine, Vol. 41, No. 37, pp. 5461–5468

Publisher

Elsevier

Publication Date

August 2023

DOI

10.1016/j.vaccine.2023.07.038

ISSN

0264-410X